Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

TechGuru,- How many patients we will have in our

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155485
(Total Views: 496)
Posted On: 12/26/2019 10:27:39 AM
Posted By: misiu143
Re: TechGuru #13651
TechGuru,-
How many patients we will have in our combo will depend of education we will give to doctors and our patients.

Combo will be approve for MDR-3 and MDR-2 will limitation to other drugs .
Because almost every patient has some side effects with HAART , they all really have limitations , so this is very easy for doctors to prove...

We expect to see over 180,000 patients in USA only , in 2020 with MDR-2 who are R-5 HIV strain.
The only competition here is Maraviroc with it severe side effects , possibilities of resistance and efficacy of 45% , compare to 81% with 350 mg dose with Leronlimab , and not one severe side effect so far ..

If I will take care of these over 180,000 patients , knowing what I know about Leronlimab and HAART ,
all my patients will be on Leronlimab ,first to prevent development of MDR-3 , when patients are very sick already , I will also stop all HAART with the most side effects , like tenofovir which we know now is very suspicious of producing NASH , and to diminished possibilities of other problems from those drugs.

MDR-3 in USA we expect about 10,000 R-5 strain in 2020.

Competition here is also Maraviroc with 45% efficacy
and
Ibalizumab , every 2 weeks IV infusion , with some side effects and efficacy of 43%. , compare to 81% with Leronlimab.


So we could see that how many patients we will have will depend how educated are doctors and patients...
And as a rule HIV positive patients are one of the most educated group of patients.



All IMO as always.










(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us